Propranolol in Primary Progressive Aphasia

Aphasia, Primary Progressive Clinical Trial

Official title:
Trial of Propranolol in Older Adults With Primary Progressive Aphasia

Status Recruiting

Clinical Trial Summary

The purpose of this study is to find out how the language of people with Primary Progressive Aphasia is affected by Propranolol. Propranolol is not FDA approved for the treatment of Primary Progressive Aphasia. Propranolol is FDA approved for the treatment of heart conditions such as blood pressure. This research is being done because there are currently no drug treatment options for language impairments and anxiety often experienced by people with Primary Progressive Aphasia.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06066710
Study type	Interventional
Source	University of Missouri-Columbia
Contact	David Beversdorf, MD
Phone	573-882-6081
Email	beversdorfd@health.missouri.edu
Status	Recruiting
Phase	Early Phase 1
Start date	May 2024
Completion date	October 2026

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT02675270` - Rehabilitation and Prophylaxis of Anomia in Primary Progressive Aphasia	N/A
Not yet recruiting	`NCT05437159` - Investigating Speech Sequencing in Neurotypical Speakers and Persons With Disordered Speech	N/A
Withdrawn	`NCT03448133` - rTMS for the Treatment of Primary Progressive Aphasia: A Randomized Controlled Trial	N/A
Active, not recruiting	`NCT04937452` - Dopaminergic Therapy for Frontotemporal Dementia Patients	Phase 2